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School of Medicine, Baltimore, MDOBJECTIVES: To determine whether poly (ADP-ribose) polymerase-1/2 (PARP-1/2) inhibition enhances radiation-
induced cytotoxicity of pancreatic adenocarcinoma in vitro and in vivo, and the mechanism by which this occurs.
Methods: Pancreatic carcinoma cells were treated with ABT-888, radiation, or both. In vitro cell viability, apoptosis,
and PARP activity were measured. Orthotopic xenografts were generated in athymic mice and treated with ABT-
888 (25 mg/kg), radiation (5 Gy), both, or no treatment. Mice were monitored with bioluminescence imaging.
RESULTS: In vitro, treatment with ABT-888 and radiation led to higher rates of cell death after 8 days (P b .01). Co-
treatment with 5 Gy and 1, 10 or 100 μmol/l of ABT-888 led to dose enhancement factors of 1.29, 1.41 and 2.36,
respectively. Caspase activity was not significantly increased when treated with ABT-888 (10 μmol/l) alone (1.28-
fold, P = .08), but became significant when radiation was added (2.03-fold, P b .01). PARP activity increased post-
radiation and was abrogated following co-treatment with ABT-888. In vivo, treatment with ABT-888, radiation or
both led to tumor growth inhibition (TGI) of 8, 30 and 39 days, and survival at 60 days of 0%, 0% and 40%,
respectively. CONCLUSIONS: ABT-888 with radiation significantly enhanced tumor response in vitro and in vivo.
ABT-888 inhibitedPARprotein polymerization resulting in dose-dependent feedback up-regulation of PARPand p-ATM
suggesting increased DNA damage. This translated into enhancement in TGI and survival with radiation in vivo. In vitro
PAR levels correlated with levels of tumor apoptosis suggesting potential as a predictive biomarker. These data are
being used to support a Phase I study in locally advanced pancreatic cancer.
Translational Oncology (2014) 7, 439–445Address all correspondence to: Richard Tuli, MD, PhD, Department of Radiation
Oncology, Cedars-Sinai Medical Center, 8700 Beverly Blvd., AC1023, Los Angeles,
CA 90048. E-mail: Richard.Tuli@cshs.org
Received 9 November 2013; Revised 11 April 2014; Accepted 14 April 2014
© 2014 Neoplasia Press, Inc. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1936-5233/14
http://dx.doi.org/10.1016/j.tranon.2014.04.003Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease
with a cumulative 5 year overall survival of 4% for all stages [1].
Current treatment of non-metastatic, unresectable disease similarly
results in dismal median survival rates of 11 to 12 months, nearly
uniform local persistence of disease and poor local control [2,3].
Indeed, recent data suggests that failure to control the primary tumor
results in complications that contribute to mortality in approximately
30% of patients [4]. To date, no treatment has had a truly significant
impact on improving outcomes in unresectable PDAC. The pivotal
trial validating gemcitabine as first-line chemotherapy for pancreatic
cancer showed a modest improvement in median survival of
6 months compared to 4 months with 5-fluorouracil [5]. Gemcita-
bine has also been shown to enhance radiosensitivity of pancreatic
cancer cells in laboratory and clinical studies [6]. A Phase I study
evaluated radiotherapy dose escalation using three-dimensional
conformal techniques with full-dose gemcitabine (1000 mg/m2),yet it was not possible to escalate the dose beyond 36 Gray (Gy;
2.4 Gy daily fractions) secondary to gastrointestinal (GI) toxicities
[7]. In an attempt to minimize dose-limiting toxicities to organs-at-
risk and simultaneously allow an increase in tumor dose, Ben Josef
et al. recently reported excellent outcomes (response rate of 52%,
median overall survival 23 months) using dose-escalated IMRT
combined with full-dose gemcitabine [8]. A potential mechanism to
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with chemo- and radiosensitizing properties that have minimal
intrinsic cytotoxicity.
Targeting of the poly (ADP-ribose) polymerase-1/2 (PARP-1/2)
proteins is one such strategy with immense potential. PARP
activation and poly (ADP-Ribose) polymerization represent one of
the first in a coordinated series of events following single- and double-
strand DNA damage repair, through the base excision repair (BER)
and non-homologous end-joining (NHEJ) pathways, respectively
[9–11]. Based on conserved genetic sequences, encoded for by 18
different genes, 18 nuclear proteins have been classified as members of
the PARP superfamily. The superfamily is further subdivided into
three branches, the PARP-1 group, the tankyrase group, and other
PARP enyzmes. The PARP-1 group of NAD+-dependent enzymes
has been extensively studied, and its members PARP-1 and PARP-2
are generally considered as the primary enzymes involved in DNA
repair [12]. Enhanced PARP-1 expression and activity has been
demonstrated to be higher in tumor cells, such as lymphoma,
hepatocellular carcinoma, and cervical carcinoma, as compared to
normal cells, which in turn is felt to confer increased drug resistance
[13]. However, when PARP is impaired, cells are noted to become
exquisitely sensitive to DNA damaging agents such as radiotherapy
[14,15]. As a result, the clinical development of PARP inhibitors has
followed two approaches: 1) combining PARP1/2 inhibition with
DNA-damaging agents, such as radiation, to derive additional
therapeutic benefit; and 2) targeting tumor cells with pre-existing
defects in double-strand DNA break repair, such as Brease Cancer
(BRCA)-deficient cells, which are genetically predisposed to die when
PARP activity is lost [16].
ABT-888 is an orally available, small molecule inhibitor of PARP
which has been shown to potentiate the effects of alkylators and
radiotherapy in xenograft tumor models [17]. Recognizing the
therapeutic potential of PARP-1/2 inhibition in PDAC, we have
investigated the addition of veliparib to focused radiation in vitro and
in vivo using a novel preclinical pancreatic cancer radiation research
model [18,19].
Materials and Methods
Cell Culture and In Vitro Assays
The PDAC cell line, MiaPaCa-2, stably transfected with the
luciferase-aminoglycoside phosphotransferase fusion gene under the
control of the elongation factor-1α promoter, was kindly provided by
Dr. Ralph Graeser, ProQinase GMBH, Freiburg, Germany. Cells
were grown in Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine
serum, and 100 units/mL penicillin/streptomycin. Subconfluent cell
monolayers were removed using 0.25% trypsin containing 1 mmol/L
EDTA (Invitrogen) and passaged at a ratio of 1:3 or utilized for study.
Cells were seeded in triplicate monolayer and treated with varying
doses of ionizing radiation using a 137Cs irradiator (5 Gy/min; Mark I,
Shepherd and Associates), ABT-888 (Selleck Chemicals, Houston,
TX), or a combination of the two. All in vitro studies were performed
in triplicate. When cells were co-treated, ABT-888 was added to the
cell suspension 30 minutes prior to irradiation and left until routine
media change at 48 hours. Cell viability was determined by the ability
to convert a redox dye (resazurin) into a fluorescent end product
(resorufin) using the Cell Titer-Blue® Assay (Promega Corporation,
Madison, WI) at varying time points after treatment. Treatmentdoses resulting in 10% (IC10), 20% (IC20) and 50% (IC50) cell
death were calculated for ABT-888 and irradiation, respectively.
ABT-888 dose enhancement factors were determined after co-
treatment with varying irradiation doses. Levels of apoptosis were
determined using a chemiluminescent caspase 3/7 assay (G8091,
Promega Corporation, Madison, WI) 48 hours after treatment with
ABT-888, radiation, or a combination thereof. PARP-1/2 inhibition
was quantitated using an enzyme-linked immunosorbent assay for
PAR protein (Trevigen, Gaithersburg, MD) after treatment with
ABT-888, radiation, ABT-888 plus radiation, or no treatment. Total
protein extracts were harvested 6 hours after treatment and PAR
levels were determined by chemiluminescence.
Immunoblotting
MiaPaCa-2 nuclear extracts were isolated after treatment with ABT-
888, radiation, or combinations thereof. Cytosolic extracts were
harvested following addition of a buffer (50 mmol/L Tris-HCl,
pH 7.4, 0.14 MNaCl, 1.5 mmol/L MgCl2, protease and phosphatase
inhibitors, PMSF, 1 mmol/L DTT). Nuclear pellets were then
suspended in RIPA buffer and nuclear proteins were harvested. Protein
quantification was performed with the Bradford DC assay (BioRad,
Hercules, CA). Immunoblotting of nuclear lysates was performed with
the following monoclonal mouse antibodies: PARP-1 (NB100-111;
Novus Biologicals, Littleton, CO) and phosphorylated ATM (p-ATM;
Ser1981, 10H11.E12, Mouse mAb #4526 Cell Signaling, Danvers,
MA) and the following polyclonal rabbit antibodies: PAR (4336-BPC-
10; Trevigen, Gaithersburg, MD) and Lamin-A (sc-20680, Santa Cruz
Biotechnology, Santa Cruz, CA). Infrared dye-conjugated secondary
antibodies were used and imaged using the Odyssey® imaging system
(Li-Cor Biotechnology, Lincoln, Nebraska).
Pancreatic Tumor Xenografts and Imaging
Six-week old female athymic nude mice (Harlan Sprague Dawley,
Madison, WI) were used in accordance with institutional Animal
Care and Use Committee guidelines under an approved protocol.
Mice were anesthetized by intraperitoneal injection of 10:1
ketamine/xylazine and 2 × 106 cells in a 1:1 mixture with Matrigel
(356235, BD Matrigel™ Basement Membrane Matrix; Becton
Dickinson, Franklin Lakes, NJ) were injected into the tail of the
pancreas per previously established protocols [19]. Two-dimensional
bioluminescence imaging (BLI) was performed with the IVIS®
Spectrum (Caliper Life Sciences, Hopkinton, MA) to allow image-
guided delivery of radiation and longitudinal assessment of treatment
response. Prior to imaging, mice were anesthetized and injected
intraperitoneally with 150 mg/kg D-luciferin (Catalog No.
LUCNA, Gold Biotechnology, St. Louis, MO) in sterile PBS.
After a 10 second exposure and image acquisition, the coronal
optical pseudocolor image was overlaid upon a corresponding
grayscale photographic image of the animal and a region of interest
was created around the optical tumor image so that the luminescence
at the edge of the circle was 5% of the peak intensity of that region
[18–20]. Signal intensity was quantified within an identified region
of interest in photons per second per squared centimeter per
steradian (p/s/cm2/sr) using Living Image software (Caliper Life
Sciences, Hopkinton, MA). Treatment-related fold-tumor change
was determined longitudinally as a function of time by normalizing
signal intensity to that obtained on day 0, as previously described
[19]. All mice in each treatment cohort were imaged simultaneously
with BLI five minutes post injection of substrate.
Figure 1. In vitro survival curves of MiaPaCa-2 cells treated with
varying doses of RT (A), ABT-888 (B) or both (C). Half-maximal half
inhibitory concentration (IC50) of RT was noted to be 5 Gy and IC10
for ABT-888 was 10 μmol/l. Co-treatment with 5 Gy and 1, 10 or
100 μmol/l of ABT-888 led to dose enhancement factors of 1.29,
1.41 and 2.36, respectively. Means and SEM are plotted.
Translational Oncology Vol. 7, No. 3, 2014 PARP inhibitor and Radiation for Pancreatic Cancer Tuli et al. 441In Vivo Treatment
Three days after surgery, all mice were imaged for development of
solitary pancreatic tumors using BLI. Tumor bearing mice were
randomized to receive one of four treatments (n = 7 per group):
vehicle alone (i.p. PBS), a single dose of ABT-888 (i.p. 25 mg/kg), a
single fraction of radiation (5 Gy), or the combination of radiation
and ABT-888. Sham treatment or ABT-888 was administered
30 minutes prior to irradiation. Anesthetized mice were imaged with
BLI and subsequently transported to the small animal radiation
research platform (SARRP). Using the guidance software utility of the
SARRP, bioluminescent images were co-registered by manual fusion
with CBCT images and the isocenter of the tumor was identified and
aligned with the central axis of the beam, as previously described 20.
Mice were irradiated with the SARRP using 225 kVp x-ray beams at a
dose rate of 2.5 Gy/minute using varying collimator widths adapted
to the optical image of the tumor (gross tumor volume) plus a 5 mm
radial margin for set up error (planning target volume). Mice
underwent BLI twice per week until day 9 and weekly thereafter to
assess tumor response and were humanely euthanized when
moribund, if they experienced weight gain or loss in excess of 20%
of pre-treatment weight, or if tumor burden increased more than 10-
fold as determined by BLI.
Statistical Analysis
Two-tailed Student’s t test was utilized to assess statistically
significant differences between groups (P b .05). Kaplan-Meier curve
was constructed for survival analysis with log-rank test.
Results
Effects of Radiation and ABT-888 on Cell Viability
The effects of increasing doses of radiation and ABT-888,
individually and concurrently, on cell viability were assessed to
determine levels of radiation dose-enhancement (Figure 1). Signif-
icant reductions in cell viability were seen with single-fraction
radiation doses exceeding 2 Gy at 2, 4, 6 and 8 days post-treatment.
The IC10, IC20 and IC50 of radiation were calculated to be 0.5 Gy,
2 Gy and 5 Gy, respectively (Figure 1A, 6 days post-treatment).
Increasing doses of ABT-888 had little effect on cell viability until
doses exceeding 5 μmol/l were used. The IC10 for treatment with
ABT-888 alone was calculated to be 10 μmol/l and this dose was
utilized for subsequent in vitro studies (Figure 1B). Significant
radiosensitization was noted when ABT-888 was added to cells
irradiated with vehicle alone. Co-treatment with 1 μmol/l, 10 μmol/l
and 100 μmol/l of ABT-888 led to radiation dose enhancement
factors of 1.29, 1.41 and 2.36 (P b .05), respectively (Figure 1C).
Minimal intrinsic cytotoxicity was noted when cells were treated with
ABT-888 alone at these same doses.
DNA damage response following treatment with radiation and
ABT-888
Radiation-induced DNA damage results in relatively immediate
activation of PARP and accumulation of ribosylated protein products,
such as PAR, primarily through single-strand breaks and BER.
Therefore, PARP and PAR protein levels were measured as a function
of time to assess the impact of treatment with radiation. An
immediate and significant increase was noted in PAR levels following
treatment with 10 Gy consistent with single-strand DNA damage,
which persisted through the 30 minute time point before returning to
control levels (Figure 2A). Conversely, PARP levels were reducedfollowing irradiation relative to controls over the same period and also
returned to baseline levels 60 minutes post-treatment. Additionally,
cells were treated with increasing doses of ABT-888 to assess the level
of PARP-1/2 inhibition and resulting PAR protein formation. A clear
dose dependent reduction in PAR levels was noted with complete
abrogation with doses of 100 μmol/l and above at both 15 and
Figure 2. Immunoblot ofMiaPaCa-2 cells treated with RT (A; +/− 10 Gy), ABT-888 (B; 0-1 mmol/L) or both (C; 10 Gy, 100 μmol/l ABT-888).
Extracts were probed for PAR, PARP, p-ATM and Lamin A.
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selected for co-treatment with radiation (Figure 2B). A corresponding
dose dependent increase in PARP protein was noted as early as
15 minutes following treatment with ABT-888 alone, and PARP
levels remained elevated as a function of time in the presence of the
treatment drug (Figure 2B). Interestingly, ABT-888 (100 μmol/l)
completely abrogated radiation-induced PAR formation to undetect-
able levels at both early time points (Figure 2C). PARP protein levels
were again noted to be inversely proportional to PAR protein
formation with significant up-regulation following treatment with
ABT-888 likely as a result of feedback inhibition. Phosphorylated-
ATM levels were up-regulated after radiation treatment relative to
controls and further induced following co-treatment with ABT-888.Figure 3. In vitro ELISA-based quantitation of PAR levels 6 hours post
apoptosis were determined using a chemiluminescent caspase 3/7 a
μmol/l), RT (2 Gy), or both (B). Means and standard error of the meaInhibition of PARP Activity and Enhanced Apoptosis with
Concurrent ABT-888
A PAR ELISA was utilized to assess the effect of radiation with and
without ABT-888 on PARP activity and to provide a quantitative
means of assessing PARP-inhibition. Six-hours post-treatment with
2 Gy (IC20), led to significant 23% increase in PARP activity relative
to untreated controls (P b .05; Figure 3A). This was further reduced
by 41% following co-treatment with 10 μmol/l ABT-888 (IC10;
P b .05) and similar to immunoblot data, this level of abrogated
activity was not significantly different when compared to cells treated
with ABT-888 (10 μmol/l; P b .32) alone, suggesting maximal
inhibition was occurring independent of treatment with radiation. To
help determine the mechanism of cytotoxicity, caspase 3/7 levels were-treatment with ABT-888 (10 μmol/l), RT (2 Gy), or both (A). Levels of
ssay 48 hours following treatment of MiaPaCa-2 with ABT-888 (10
n are plotted. Asterisk represents statistical significance.
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(10 μmol/l), or a combination of the two (Figure 3B). Whereas
treatment with ABT-888 alone failed to induce significant caspase-3/7
activity, treatment with radiation led to a 1.69-fold increase (P b .05) in
levels relative to untreated controls and these were further enhanced to
1.99 (P b .05) following the addition of ABT-888 suggesting increased
apoptotic cell death.
Enhanced Radiation-Induced Tumor-Growth Inhibition and
Survival with ABT-888
Utilizing a previously reported small animal pancreatic cancer radiation
research model, MiaPaCa-2-derived orthotopic tumors were treated with
BLI-guided, focused radiation (5 Gy), ABT-888 (25 mg/kg), or a
combination of the two [19]. Co-treatment with ABT-888 resulted in
significant tumor growth inhibition of 36 days relative to controls treatedFigure 4.Orthotopic MiaPaCa-2 tumors were treated with saline sham
using bioluminescence imaging (A). Tumor growth inhibition of 8, 30
respectively (B).with saline sham injection (Figure 4). This was significantly greater than
tumors treated with either radiation (28 days) or ABT-888 (10 days)
alone. The addition of ABT-888 to radiation also translated into a
significant overall survival benefit compared to either treatment alone
(Figure 5). Survival at 30 days formice treatedwithABT-888, radiation or
a combination of the two was 63%, 75% and 100%, respectively, while at
60 days, it was 0%, 0% and 29% (P b .05), respectively. Of note, mice in
the combination treatment group died more often as a result of metastatic
disease, ascites, excessive weight loss or failure to thrive, as compared to
mice treated with either modality alone, which died more frequently from
growth of the primary tumor as assessed by BLI (data not shown).
Discussion
Herein, we demonstrated that the addition of ABT-888 to radiation
significantly enhanced tumor response of pancreatic cancer cells in, ABT-888 (25 mg/kg), RT (5 Gy), or both and followed longitudinally
and 39 days was noted compared to treatment with saline sham,
Figure 5. Orthotopic MiaPaCa-2 tumors were treated with saline
sham, ABT-888 (25 mg/kg), RT (5 Gy), or both. Survival at 30 days
for mice treated with ABT-888, RT or a combination of the two was
63%, 75% and 100%, respectively, while at 60 days, it was 0%,
0% and 29% (P b .05, ABT + RT vs. all other treatments).
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resulting in dose-dependent feedback up-regulation of PARP enzyme,
as well as p-ATM suggesting increased DNA damage and potential
repair by mechanisms such as homologous recombination (HR). This
translated into significant enhancement in tumor growth inhibition
and survival when combined with focused image-guided radiation of
orthotopic pancreatic xenografts.
Several studies have examined the mechanism of cell-death induced
following PARP inhibition. Similar to our study, Horton et al. have
suggested that inhibition of PARP activity results in a caspase-
dependent apoptotic programmed cell death, as inhibition of caspase
and Chk1 resulted in increased necrotic cell death as well as
percentage of viable cells, respectively [21]. Interestingly, other
studies have suggested no difference in the percentage of apoptotic
cells following PARP inhibition, or mechanisms independent from
apoptosis, such as mitotic catastrophe [22,23]. Liu et al. suggest this
may be a cell-line dependent phenomenon; irrespective, we noted
that the increased cytotoxicity seen following the addition of ABT-
888 to radiation was at least in part mediated through increased
caspase activity and programmed cell death [24].
Significant and immediate induction of PAR protein was noted
following radiation, as previously reported, with dose-dependent
attenuation following PARP-inhibition in the pancreatic cancer cells.
Following PARP inhibition, we identified a coincident up-regulation
of radiation-induced p-ATM, which is a key regulator of homologous
recombination following double-strand DNA breaks. Similar to our
study, Metzger et al. recently reported a 1.7-fold increase in the rate of
nick-induced HR following PARP inhibition without affecting DSB-
induced HR utilizing an integrated reporter system in human cells to
measure HR and non-homologous end-joining [25]. These findings
further confirm PARP-1 as a primary mediator in single-strand DNA
repair and further allude to the significance of interplay with BRCA1/
2-mediated DSB repair and the potential clinical significance of
synthetic lethality. In addition to inhibiting the catalytic activity of
PARP, Murai et al. recently reported on a novel secondary
mechanism of action of PARP inhibitors [26]. This involves binding
of the PARP inhibitor to the NAD+ site on the PARP enzyme,
thereby enhancing the allosteric DNA binding domain of the protein
and essentially trapping the PARP1- and PARP2-DNA complexes.
The authors concluded that this secondary trapping effect was
significantly more cytotoxic than catalytic inhibition based on the
observation that olaparib-treated wild type DT40 cells weresignificantly more sensitive to the alkylating agent, methylmethane
sulfonate (MMS), compared to PARP1−/− DT40 cells treated with
MMS alone, thereby suggesting a secondary mechanism of action
responsible for the enhanced sensitivity.
To our knowledge, this study is the first to report on ABT-888-
mediated radiosensitization of pancreatic cancer in vivo. Similar to
preclinical studies in other disease sites, we noted limited clinical
benefit of ABT-888 when used as a single-agent. However, in
combination with radiation, we saw at least an additive effect of
treatment on survival. Whereas these findings were consistent with in
vitro results, the benefit was not as robust, and may be attributable to
differences in treatment dose(s) and method of treatment delivery
among other factors. We believe, however, that these clinical findings
are appropriately representative of whatmight be expected in the clinical
setting given the novel preclinical platform (SARRP) used to deliver
radiation [19]. Similar to clinical studies, the potential therapeutic
benefit of PARP-inhibition with ABT-888 may be further potentiated
when used in combination with radiosensitizing chemotherapeutic
agents. Jacob et al. have reported on the gemcitabine-sensitizing effects
of the PARP-inhibitor, 3-aminobenzamide [27]. Co-treatment of
heterotopic Capan-1 pancreatic tumors in mice with both agents
resulted in a significant synergistic improvement in survival relative to
either treatment alone. As a fluorine-substituted analog of cytarabine,
the primary mechanism of gemcitabine cytotoxicity is due to
impairment of DNA synthesis through inhibition of DNA polymerase
and ribonucleoside reductase by gemcitabine diphosphate and
triphosphate with subsequent depletion of deoxyribonucleotide pools
necessary for DNA synthesis [28]. As these mechanisms seem
independent of PARP-regulated SSB DNA repair, the mechanism of
potential synergism with gemcitabine remains unclear. Consistent with
the findings of Jacob et al, however, we have noted similar dose
enhancement and cytotoxicity following co-treatment of MiaPaCa-2
cells with radiation, gemcitabine and ABT-888 further suggesting that
ABT-888 acts as both a radiation- and chemo-sensitizer. A recent
clinical study compared full dose gemcitabine (1000 mg/m2) to a lower
dose of gemcitabine (600 mg/m2) combined with standard fraction-
ated radiation (50.4 Gy over 5.5 weeks) in patients with locally
advanced PDAC [29]. Although the study was closed prior to reaching
its planned accrual, there was a significant improvement in survival
with combined gemcitabine and radiation compared to gemcitabine
alone. Recognizing the potential benefits of combining gemcitabine
with radiotherapy for patients with locally advanced pancreatic cancer,
future treatment strategies could aim to further exploit this synergy
through PARP-inhibition.
The concept of synthetic lethality applies to cells with impaired HR,
which are further subjected to PARP-1/2 inhibition. The resulting
single-stranded DNA breaks ultimately lead to an accumulation of
double-strand breaks that cannot be effectively repaired, culminating in
complex chromosomal alterations and increased levels of apoptosis [30].
Indeed, Cass et al. have reported on the improvement in survival in
patients with BRCA-associated ovarian carcinoma treated with
cisplatin, and more recently, Fogelman et al. reported a case of a
pancreatic adenocarcinoma patient with germline BRCA-2 mutation
who demonstrated complete pathologic response to the PARP-
inhibitor, BSI-201 [31,32]. Henessy et al. recently investigated the
frequency of somatic and germline BRCA-1/2 mutations in ovarian
cancer and attempted to correlated these findings to progression-free
survival after treatment with cisplatin [33]. Interestingly, 30% of all
patients had either germline or somatic BRCA-1/2 mutations and
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outcomes relative to patients not harboring these mutations. These data
suggest that PARP-inhibitor therapy may be most appropriate not only
for the 17% of pancreatic cancer patients who harbor BRCA-1/2
germline mutations, but also those harboring somatic mutations in
other proteins involved in HR repair, such as mutated partner and
ligand of BRCA2 (PALB2) and phosphatase and tensin homolog
deleted on chromosome 10 (PTEN) [34,35]. Based on the results
presented herein, as well as the clinical success of PARP-inhibitors to
date, we have initiated a Phase 1 study investigating the maximum
tolerated dose, safety and toxicity of ABT-888 with full dose
gemcitabine and intensity modulated radiotherapy in patients with
locally advanced PDAC.
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